Reimbursement policies of Swiss health insurances for the surgical treatment of symptomatic breast hypertrophy: a retrospective cohort study.

Abstract

Background: Patients with symptomatic breast hypertrophy typically suffer from chronic back pain, recurrent skin irritation at the inframammary fold and/or low self-esteem resulting in impaired quality of life. Reduction mammaplasty has been shown to effectively treat symptomatic breast hypertrophy with high patient satisfaction. Despite the obvious benefits, reimbursement requests for reduction mammaplasty are initially often refused by the patient's health insurance company, thereby frequently resulting in additional examinations and eventually extra expenses. The study aim was to evaluate the reimbursement policy by health insurance companies for treatment costs of reduction mammaplasty in a patient cohort, to quantify the generation of additional costs due to initial refusal of reimbursement, as well as to assess back pain after surgical treatment.

Methods: A retrospective cohort study was conducted in two Swiss centres. Inclusion criteria were a diagnosis of symptomatic breast hypertrophy, cost approval for reduction mammaplasty by the health insurance between October 2014 and March 2021 and informed consent for the study. The exclusion criteria were private payers for reduction mammaplasty and patients aged below 18. Primary outcome measures included median duration between the first request for reimbursement sent to the health insurance and the receipt of its approval, the number of requests needed per patient, as well as the number and type of additional outpatient visits conducted by specialists other than plastic surgeons, including the need for further diagnostic investigations and therapeutic measures. Secondary outcome measures included the additional costs generated in patients with more than one request. Finally, back pain after surgical treatment was assessed using a visual analogue scale (VAS).

Results:  A total of 46 patients with symptomatic breast hypertrophy and approval for reimbursement were included in the study. The median duration to obtain cost approval for reduction mammaplasty was 9.4 weeks (ranging from 1 to 154 weeks). Reimbursement was approved after 1, 2, 3 or 4 requests in 26, 6, 11 and 3 patients, respectively. If the first request was refused, further clinical evaluation by specialists, additional imaging of the cervical spine and physiotherapy was necessary in 70%, 35% and 80% of the patients, respectively. A patient requiring more than one request to obtain cost approval for reduction mammaplasty generated additional mean costs of approximately 2400 CHF, i.e. 2181 CHF, 164 CHF and 46 CHF for ongoing physiotherapy, additional outpatient visit by a specialist doctor and complementary imaging compared to patients needing only one request for cost approval. The level of back pain could be reduced from 7.0 before surgery to 1.6 after surgery.

Conclusion:  Patients with symptomatic breast hypertrophy who needed more than one request for cost approval (43%) had to undergo further outpatient visits and/or radiological examinations, as well as physiotherapy, despite a clear indication for surgery, resulting in a prolonged symptomatology and increasing healthcare costs.